Pi Therapeutics is a preclinical-stage pharmaceutical company developing modulators of protein degradation, including a novel first-in-class inhibitor that has shown encouraging preclinical activity in liquid and solid tumor models. The company was established in 2015 based on technology in‑licensed from Johns Hopkins University and is led by CEO Dr. Ori Kalid. Pi is advancing its lead program toward clinical proof-of-concept and will use proceeds from the financing to support that work. The company is based in Ness Ziona, Israel. Financially, Pi has raised approximately $24M to date, including the newly completed Series B. The company focuses exclusively on oncology therapeutics built on targeted protein degradation.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

May 2019